GENERICSWEB - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/194781.xml GENERICSWEB - Press Releases en xml@emediawire.com xml@emediawire.com 30 GenericsWeb's Pipeline Scope Helps Avoid Costly Patent Litigation http://www.prweb.com/releases/2008/11/prweb1404324.htm GenericsWeb's latest product, Pipeline Scope, contains the comprehensive, accurate and regularly updated patent information needed to ensure that the planned launch of a generic pharmaceutical product is not delayed. An example of how incomplete and inaccurate information can lead to costly litigation and a delayed product launch follows below. (PRWeb Nov 14, 2008)

Read the full story at http://www.prweb.com/releases/2008/11/prweb1404324.htm

]]> http://www.prweb.com/releases/2008/11/prweb1404324.htm Launching the Indian Generic Pharmaceutical Patent Academy - Understand and Respond to Patents http://www.prweb.com/releases/2008/09/prweb1314204.htm GenericsWeb is thrilled to announce that the Generic Pharmaceutical Patent Academy is travelling to India for two events. (PRWeb Sep 12, 2008)

Read the full story at http://www.prweb.com/releases/2008/09/prweb1314204.htm

]]> http://www.prweb.com/releases/2008/09/prweb1314204.htm Accurate and Complete Expiry Information Now Available with GenericsWeb Pipeline Scope http://www.prweb.com/releases/2008/07/prweb1079114.htm Finally, the generics industry has fast access to reliable key patent, SPC and data protection expiry information. Pipeline Scope, the latest release from industry experts GenericsWeb provides accurate and complete data for over 1400 INNs, across 37 countries, delivered through an interface that is easy to use and interpret. (PRWeb Jul 8, 2008)

Read the full story at http://www.prweb.com/releases/2008/07/prweb1079114.htm

]]> http://www.prweb.com/releases/2008/07/prweb1079114.htm GenericsWeb Opens U.S. Doors http://www.prweb.com/releases/2008/07/prweb1070704.htm GenericsWeb, provider of premium Patent Intelligence Services to the Generic Pharmaceutical Industry, today opened the doors of its first US offices, strategically located in Morristown, New Jersey, the heart of the US pharmaceutical industry. (PRWeb Jul 3, 2008)

Read the full story at http://www.prweb.com/releases/2008/07/prweb1070704.htm

]]> http://www.prweb.com/releases/2008/07/prweb1070704.htm GenericsWeb -- Tolterodine Polymorph Patent Highlights Ongoing Quality Issues in USPTO http://www.prweb.com/releases/2007/12/prweb583212.htm The intended allowance of a patent to a generic manufacturer which essentially protects any polymorphic form of tolterodine tartrate together with a carrier or diluent demonstrates that the quality of patent examination at the USPTO cannot be relied upon to filter out patent applications that are clearly not innovative from the eyes of a generic developer and that may significantly affect the level of generic competition to Pharmacia & Upjohn's Detrol product post patent expiry. (PRWeb Dec 19, 2007)

Read the full story at http://www.prweb.com/releases/2007/12/prweb583212.htm

]]> http://www.prweb.com/releases/2007/12/prweb583212.htm Launching Generic Pharmaceutical Patent Academy - Understand and Respond to Patents http://www.prweb.com/releases/2007/04/prweb518773.htm GenericsWeb is delighted to announce the inaugural Generic Pharmaceutical Patent Academy, to be held on the 8th-10th of May in London. This is an exciting opportunity for those in the generic pharmaceutical industry to improve their understanding and effectiveness in a rapidly evolving industry. (PRWeb Apr 15, 2007)

Read the full story at http://www.prweb.com/releases/2007/04/prweb518773.htm

]]> http://www.prweb.com/releases/2007/04/prweb518773.htm Levitra® - Opportunity for Proactive Generic Companies? http://www.prweb.com/releases/2007/03/prweb513795.htm The recently released GenericsWeb Pipeline Developer patent report for Levitra® (Vardenafil) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product's lifecycle. (PRWeb Mar 26, 2007)

Read the full story at http://www.prweb.com/releases/2007/03/prweb513795.htm

]]> http://www.prweb.com/releases/2007/03/prweb513795.htm Esomeprazole Remains Under Threat http://www.prweb.com/releases/2007/02/prweb502144.htm Following the recent revocation by the EPO of a key patent in the array of protection of AstraZeneca's Nexium (Esomeprazole) there remains a degree of uncertainty as to whether it opens the door for generic competition according to a recent analysis by Generic Patent Intelligence experts at GenericsWeb.com. (PRWeb Feb 3, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb502144.htm

]]> http://www.prweb.com/releases/2007/02/prweb502144.htm More to Veterinary Anthelmintic ProHeart than Green Book Indicates http://www.prweb.com/releases/2006/11/prweb469803.htm Analysis of the GenericsWeb Pipeline Patent Intelligence for Wyeth's top selling veterinary anthelmintic ProHeart® (Moxidectin) shows that generic manufacturers should be wary of relying upon the US FDA Green Book for their critical patent expiry information. (PRWeb Nov 6, 2006)

Read the full story at http://www.prweb.com/releases/2006/11/prweb469803.htm

]]> http://www.prweb.com/releases/2006/11/prweb469803.htm Avandia® Patents Afford Protection Against Generic Competition http://www.prweb.com/releases/2006/09/prweb433624.htm Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb. Analysis of their Pipeline Patent Intelligence reveals that the patent situation surrounding this product is very complex, and is likely to be problematic for lesser-informed generic developers, especially those developing for multiple markets. (PRWeb Sep 7, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb433624.htm

]]> http://www.prweb.com/releases/2006/09/prweb433624.htm Full Story of Relpax Patent Protection Not Told by Orange Book http://www.prweb.com/releases/2006/05/prweb378781.htm Pfizer’s oral anti-migraine medicine Relpax, (Eletriptan hydrobromide) appears to have more patent protection than meets the eye. A report by GenericsWeb has uncovered an array of patent protection in terms of molecular form, active ingredient synthesis, formulations and medical use of not only the commercial product but also of potential commercial alternatives for generic competitors. (PRWeb May 1, 2006)

Read the full story at http://www.prweb.com/releases/2006/05/prweb378781.htm

]]> http://www.prweb.com/releases/2006/05/prweb378781.htm GenericsWeb Launches Generic Pharmaceutical Business Intelligence Database ‘RMF’ http://www.prweb.com/releases/2006/04/prweb374425.htm GenericsWeb announces the launch of RMF (Research Master File), bringing together the generic pharmaceutical industry’s most reputable publishers to create an industry-dedicated online business intelligence portal. (PRWeb Apr 20, 2006)

Read the full story at http://www.prweb.com/releases/2006/04/prweb374425.htm

]]> http://www.prweb.com/releases/2006/04/prweb374425.htm